METABANK评分:预测寡转移性疾病立体定向放疗后生存的临床工具
该研究纳入2003至2017年在本中心接受立体定向放疗的1-5个寡转移灶患者403例(760个转移灶),随机分为训练集(2/3)与验证集(1/3),建立Cox回归模型并赋予风险分值。共识别男性、同时性寡转移、脑转移、非腺癌组织学、KPS<80五个独立不良因素,形成METABANK评分并划分四组,中位总生存从0-2分组的41.2个月至14-28分组的7.9个月。
要点
- 五个独立不良因素为男性、同时性寡转移、脑转移、非腺癌组织学、KPS<80,分别赋分4、2、7、7、8分。
- 评分分为四组:0-2分中位生存41.2个月,3-8分29.3个月,9-13分17.4个月,14-28分7.9个月。
- 该评分可用于新试验中的患者分层及寡转移患者的个体化诊疗支持。
核心结论
- 作者提出一种可适用于多种原发肿瘤和疾病部位(包括脑转移)的预后评分,列线图和风险分组可用于新试验中的患者分层并支持寡转移患者的个体化诊疗。
研究设计与样本
- 研究纳入2003至2017年在本中心接受立体定向放疗的1-5个寡转移灶的全部患者,随机分为模型训练集(2/3)和独立的验证集(1/3),建立并验证Cox回归模型,对所得参数赋予风险分值。
主要发现
- 共403例患者接受立体定向放疗,治疗760个转移灶;治疗部位主要为肺、肝、淋巴结区和脑,最常见原发肿瘤为结直肠癌和肺癌。
- 存活患者中位随访达42个月,中位总生存为26.6个月(95%CI 23.8-29.3)。
- 共识别五个独立不良因素:男性、同时性寡转移、脑转移、非腺癌组织学、KPS<80;风险评分由各因素分值相加构成(男性4分、同时性2分、脑转移7分、非腺癌7分、KPS<80为8分)。
- 四个风险组的中位总生存分别为:0-2分组41.2个月(95%CI 30.2-52.3),3-8分组29.3个月(95%CI 24.6-34.0),9-13分组17.4个月(95%CI 10.1-24.7),14-28分组7.9个月(95%CI 5.5-10.3)。
关键数值与推荐
- 风险评分由五个因素分值相加构成:男性4分、同时性寡转移2分、脑转移7分、非腺癌组织学7分、KPS<80为8分。
- 风险分组:0-2分、3-8分、9-13分、14-28分,对应中位总生存分别为41.2个月(95%CI 30.2-52.3)、29.3个月(95%CI 24.6-34.0)、17.4个月(95%CI 10.1-24.7)、7.9个月(95%CI 5.5-10.3)。
临床怎么用
- 作者提出该预后评分可适用于多种原发肿瘤和疾病部位(包括脑转移),列线图和风险分组可用于新试验中的患者分层并支持寡转移患者的个体化诊疗。
- 在线计算器将在predictcancer.org上线。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Stereotactic radiotherapy (SRT, SBRT) is widely used in oligometastatic cancer, but the heterogeneity of the population complicates estimation of the prognosis. We investigated the role of different clinical and inflammatory parameters. MATERIALS AND METHODS: We included all patients treated with SRT for 1-5 oligometastases between 2003 and 2017 in our center. Patients were randomized between a model training set (2/3) and a separate validation set (1/3). A Cox regression model was built, validated and risk points were attributed to the resulting parameters. RESULTS: 403 patients received SRT for 760 metastases. Treated sites were mainly lung, liver, nodal areas, and brain. Most common primaries were colorectal and lung cancer. Median follow-up for living patients reached 42 months and median overall survival (MS) was 26.6 months (95% CI 23.8-29.3). Five independent adverse factors were discriminated: male sex, synchronous timing of oligometastases, brain metastasis, non-adenocarcinoma histology, KPS <80. A risk score is formed by summation of the points of each factor (M:4, T:2, B:7, N:7, K:8). Four risk groups were defined: (1) 0-2 points: MS 41.2 months (95% CI 30.2-52.3); (2) 3-8 points: 29.3 months (24.6-34.0); (3) 9-13 points: 17.4 months (10.1-24.7), and (4) 14-28 points: 7.9 months (5.5-10.3). CONCLUSION: We propose a prognostic score applicable in a variety of primary tumors and disease locations, including presence of brain metastases. The nomogram and risk groups can be used to stratify patients in new trials and to support individualized care for oligometastatic patients. An online calculator will become available at predictcancer.org.
引用
- Van den Begin R, Engels B, Collen C, et al. The METABANK score: A clinical tool to predict survival after stereotactic radiotherapy for oligometastatic disease. Radiother Oncol. 2019. PMID: 30935566. doi:10.1016/j.radonc.2019.01.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。